Grant: Master's Award: Canada Graduate Scholarships
Université de Montréal
$17,500.00
The Design and Validation of Clinical Decision-Support Algorithm for Clinicians to Help in the Prescribing of Renin-Angiotensin-Aldosterone Blockers for Diabetic Nephroprotection in Older Patients
EF 2018-19
Résumé
Chronic kidney disease is a serious condition where the kidneys’ function progressively declines, which may ultimately result in a need for kidney replacement therapy such as dialysis. After age, diabetes is the most important risk factor for developing kidney disease, as 40% of kidney disease cases were due to diabetes.
Renin-angiotensin-aldosterone blockers (RAAB) is a class of medications that have protective effects from kidney disease in patients with diabetes. Although there is an evidence on the importance of prescribing RAAB in patients with diabetes, 57% of older patients are not receiving RAAB in fear of their side effects, or underestimation of their beneficial effects in frail older patients. That would result in increased cases of older patients who end up in dialysis units and who suffer painful and costly complications. Clinicians need to incorporate knowledge from clinical trials and balance it with their patients’ unique factors (such as patients’ level of independence and remaining life expectancy) to help decide when to prescribe RAAB for their older patients.
This project aims at developing and validating a tool to aid clinicians when prescribing RAAB to older patients with diabetes. While being based on the latest medical evidence, this tool will consider the patients’ level of independence and remaining life expectancy when deciding to stop, resume or start RAAB for kidney protection. We propose to conduct a thorough literature review to design the tool and will validate its accuracy and clearness through consulting a panel of experts. The use of this tool in the daily clinical practice will ensure that older patients with diabetes will receive RAAB when eligible, and will be protected from complications of kidney disease, and dialysis eventually.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
406580
Name
Alsalemi Noor
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Design and Validation of Clinical Decision-Support Algorithm for Clinicians to Help in the Prescribing of Renin-Angiotensin-Aldosterone Blockers for Diabetic Nephroprotection in Older Patients
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Decision-Support Algorithm; Diabetic Nephropathy; Evidence-Based Medicine; Geriatrics; Medication Management; Potentially Inappropriate Prescribing; Tool Validation
Abstract
Chronic kidney disease is a serious condition where the kidneys’ function progressively declines, which may ultimately result in a need for kidney replacement therapy such as dialysis. After age, diabetes is the most important risk factor for developing kidney disease, as 40% of kidney disease cases were due to diabetes.
Renin-angiotensin-aldosterone blockers (RAAB) is a class of medications that have protective effects from kidney disease in patients with diabetes. Although there is an evidence on the importance of prescribing RAAB in patients with diabetes, 57% of older patients are not receiving RAAB in fear of their side effects, or underestimation of their beneficial effects in frail older patients. That would result in increased cases of older patients who end up in dialysis units and who suffer painful and costly complications. Clinicians need to incorporate knowledge from clinical trials and balance it with their patients’ unique factors (such as patients’ level of independence and remaining life expectancy) to help decide when to prescribe RAAB for their older patients.
This project aims at developing and validating a tool to aid clinicians when prescribing RAAB to older patients with diabetes. While being based on the latest medical evidence, this tool will consider the patients’ level of independence and remaining life expectancy when deciding to stop, resume or start RAAB for kidney protection. We propose to conduct a thorough literature review to design the tool and will validate its accuracy and clearness through consulting a panel of experts. The use of this tool in the daily clinical practice will ensure that older patients with diabetes will receive RAAB when eligible, and will be protected from complications of kidney disease, and dialysis eventually.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Alsalemi, Noor
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~